Bispecific cytokine delivers for Innovent at last
Innovent’s perseverance with a cytokine approach is rewarded with $1.2bn from Takeda.
Ipsen sees a future in gammadelta T-cells
The company will acquire ImCheck for €350m.
Licensing analysis: small deals dominate
The biggest Q3 agreement was AbbVie’s $700m swoop for Glenmark's trispecific T-cell engager.
Takeda’s cancer prospects dim further
After trimming its cell therapy pipeline last year, the group is now out entirely.
Petosemtamab secures a buyout for Merus
Genmab acquires the Dutch biotech for $8bn.
